Molecular encapsulation of amodiaquine in 2-hydroxypropyl β-cyclodextrin cavity. Characterization and its in vitro cytotoxicity

Anitha, A.; Murugan, Moorthiraman; Rajamohan, R.

doi:10.1080/00387010.2018.1448421

Cited by 8 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The negative control group was also subjected to the same conditions as the treated groups. A previous study on the in vitro cytotoxicity of amodiaquine on MDA-MB-231 cells showed that the IC 50 value obtained was 840 µg/ mL [13]. This current cell viability study showed that amodiaquine is more potent against these MDA-MB-231 cells where the IC 50 value obtained was 8.94µg/mL (19.23 µM) (Table 1).…”

Section: Discussionsupporting

confidence: 51%

“…Amodiaquine is a mannich base 4aminoquinoline anti-malarial drug, with an analogous mode of action to chloroquine [11]. It has been shown to inhibit autophagy and stabilize p53 through ribosome biogenesis stress, and as such, it has been reprofiled in the anti-cancer activity of some murine and human cancer cells [12,13]. Moreover, it has been shown to be non-cytotoxic to healthy cells like Vero cells [14,15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Screening of Amodiaquine for its in vitro Anti-cancer Activity on Breast Cancer Cell Lines- a Case Study for Drug Reprofiling

Salako

2021

PAJOLS

View full text Add to dashboard Cite

Background: Cancer is one of the foremost contributors to global disease bur den and constantly requires new therapeutic options. The development of new drugs has failed to keep up with its incidence. Hence, drug reprofiling strategies are emerging as novel therapeutic options. The study aimed to evaluate the anti-cancer activity of amodiaquine (anti-malarial drug) using a combination of murine and human breast cancer cell lines Methods: Amodiaquine was authenticated by ultra-violet spectrophotometry, high- performance liquid chromatography and 1D nuclear magnetic resonance. In vitro cytotoxicity of amodiaquine was evaluated against three breast cancer cell lines. MDA-MB-453, 4T1 and MDA-MB-231 cells were incubated with the drug at different concentrations (0.78, 1.56, 3.13, 6.25, 12.50, 25.00, 50.00, 100.00 μM) for 72 h, after which cell viability testing was conducted using the cell counting kit-8 assay. Negative control in which no drug was added to the cells was also evaluated. The flow cytometry analysis of MDA-MB-231 cells when treated with amodiaquine was also evaluated by a flow cytometer using annexin V/propidium iodide staining assay. Results: Cell viability studies showed that the IC50 values of amodiaquine on MDA-MB-453, 4T1, and MDAMB-231 cells were 6.48 ± 1.12, 10.50 ± 1.17, and 19.23 ± 1.16 μM, respectively. The flow cytometry analysis of MDA-MB-231 cancer cells treated with amodiaquine showed cancer cell death by necrosis. Conclusion: This study has shown that amodiaquine may be potentially reprofiled as an anti-cancer agent in managing androgen receptor-positive / HER-2 positive and triple-negative breast cancer types. An additional probable mechanism of action of anti-cancer activity of amodiaquine was found to be necrosis .

show abstract

Section: Discussionsupporting

confidence: 51%